Literature DB >> 7390059

Radioimmunoassay of plasma gastric inhibitory polypeptide (GIP), release of GIP after a test meal and duodenal infusion of bile, and immunoreactive plasma GIP components in man.

P G Burhol, R Jorde, H L Waldum.   

Abstract

A sensitive, precise and specific radioimmunoassay method for measuring plasma gastric inhibitory polypeptide (GIP) is described. The present assay system, using a label purified on a Sephadex G-15 and a SP Sephadex C-25 column as well as careful corrections for nonspecific plasma effects, allows measurements of fasting plasma GIP in the lower picomole per liter range, and the significant rise in plasma GIP subsequent to a test meal and duodenal infusion of cattle bile. Apparent immunoreactive fasting plasma GIP was eluted from a Sephadex G-150 Fine column in one peak probably representing plasma GIP bound to plasma proteins and nonspecific plasma effects. Apparent immunoreactive meal-stimulated plasma GIP was eluted from a Sephadex G-50 Fine column in two large and one diminutive peak. The first peak probably represents plasma GIP bound to plasma proteins and nonspecific plasma effects, the almost negligible second peak probably represents big GIP with a molecular weight of some 9,000, and the third and major peak, little GIP with a molecular weight of about 5,000.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7390059     DOI: 10.1159/000198457

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  4 in total

1.  Does gastric acid release plasma somatostatin in man?

Authors:  M R Lucey; J A Wass; P D Fairclough; M O'Hare; P Kwasowski; E Penman; J Webb; L H Rees
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

2.  Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients.

Authors:  K Tötterman; L Groop; P H Groop; R Kala; E M Tolppanen; F Fyhrquist
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 3.  Clinical aspects of GIP secretion.

Authors:  B Beck; C Villaume; G Debry
Journal:  Acta Diabetol Lat       Date:  1982 Jan-Mar

4.  The neuropeptide head activator loses its biological acitivity by dimerization.

Authors:  H Bodenmüller; E Schilling; B Zachmann; H C Schaller
Journal:  EMBO J       Date:  1986-08       Impact factor: 11.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.